Results 141 to 150 of about 15,279 (220)

Application of MPBT Assay for Multiplex Determination of Infectious Titers and for Selection of the Optimal Formulation for the Trivalent Novel Oral Poliovirus Vaccine. [PDF]

Viruses
Manukyan H, Lal M, Zhu C, Singh O, Lin TL, Tritama E, Chumakov K, Lee SM, Laassri M.   +8 more
europepmc   +1 more source

Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV. [PDF]

Risk Anal, 2021
Kalkowska DA, Thompson KM.
europepmc   +1 more source

Sequential inactivated and oral poliovirus vaccine schedules: a balancing act. [PDF]

Lancet Infect Dis, 2020
Zaman K, Anand A.
europepmc   +1 more source

Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. [PDF]

Risk Anal, 2021
Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay AS, Konopka-Anstadt JL, Burns CC, Oberste MS, Wassilak SGF, Badizadegan K, Thompson KM.   +9 more
europepmc   +1 more source

The Immunogenicity of Monovalent Oral Poliovirus Vaccine Type 1 (mOPV1) and Inactivated Poliovirus Vaccine (IPV) in the EPI Schedule of India. [PDF]

Vaccines (Basel)
Mohanty L, John TJ, Pawar SD, Ramanan PV, Agarkhedkar S, Haldar P.   +5 more
europepmc   +1 more source

A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people [PDF]

, 2015
Geun-Ryang Bae, Hye-Jin Kim, Ji-Yeon Hyeon, Kwangsook Park, Sang Won Lee, Seoyeon Hwang, Somin Lee, Yong-Seok Jeong, Young Joon Park, Yunhyung Kwon   +9 more
core   +1 more source

Development of a Quantitative One-Step RT-PCR Method for the Detection of Sabin 2 Virus Contamination in a Novel Oral Poliovirus Vaccine Type 2. [PDF]

Vaccines (Basel), 2021
Manukyan H, Tritama E, Wahid R, Ansari A, Konz J, Chumakov K, Laassri M.   +6 more
europepmc   +1 more source

Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. [PDF]

Risk Anal
Kalkowska DA, Wassilak SGF, Wiesen E, Burns CC, Pallansch MA, Badizadegan K, Thompson KM.   +6 more
europepmc   +1 more source

Assessing the mucosal intestinal and systemic humoral immunity of sequential schedules of inactivated poliovirus vaccine and bivalent oral poliovirus vaccine for essential immunization in Bangladesh: An open-label, randomized controlled trial. [PDF]

Vaccine
Snider CJ, Zaman K, Estivariz CF, Aziz AB, Yunus M, Haque W, Hendley WS, Weldon WC, Oberste MS, Pallansch MA, Wassilak SGF, Anand A.   +11 more
europepmc   +1 more source

[Vaccine-associated poliomyelitis: safety of the oral poliovirus vaccine, Brazil, 2013-2023Poliomielitis asociada a poliovirus derivados de la vacuna: seguridad de la vacuna oral contra la poliomielitis en Brasil, 2013-2023]. [PDF]

Rev Panam Salud Publica
Silva RMA, Kobayashi CD, Martins AF, Porto VBG, Araujo ACM, Andrade PHS, da Nóbrega MEB, Cabral CM, de Moraes MB, Ikeda do Carmo GM, Cardoso FD, de Siqueira GA, de Matos ZM, Percio J, Fernandes EG.   +14 more
europepmc   +1 more source